Methamphetamine Toxicity Questions & Answers

1. Richards JR, Laurin EG. Methamphetamine Toxicity. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. United Nations Office on Drugs and Crime (UNODC). Drug Market Trends: Cocaine Amphetamine-type Stimulants and New Psychoactive Substances. World Drug Report 2022: Booklet 4. United Nations publication, Sales No. 22.XI.8; June 2022. [Full Text].

3. National Survey of Drug Use and Health: 2021 NSDUH Detailed Tables. National Institute on Drug Abuse. Available at https://www.drugabuse.gov/national-survey-drug-use-health. January 4, 2023; Accessed: January 21, 2023.

4. Vearrier D, Greenberg MI, Miller SN, Okaneku JT, Haggerty DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon. 2012 Feb. 58(2):38-89. [QxMD MEDLINE Link].

5. Richards JR. Amphetamine derivatives. Cole SM. New research on street drugs. New York: Nova; 2006. chap 5.

6. Hendrickson RG, Horowitz BZ, Norton RL, Notenboom H. "Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing". Clin Toxicol (Phila). 2006. 44(4):379-82. [QxMD MEDLINE Link].

7. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med. 1999 Apr. 170(4):198-202. [QxMD MEDLINE Link].

8. Hendrickson RG, Cloutier R, McConnell KJ. Methamphetamine-related emergency department utilization and cost. Acad Emerg Med. 2008 Jan. 15(1):23-31. [QxMD MEDLINE Link].

9. Uhlmann S, Debeck K, Simo A, Kerr T, Montaner JS, Wood E. Crystal methamphetamine initiation among street-involved youth. Am J Drug Alcohol Abuse. 2013 Nov 5. [QxMD MEDLINE Link].

10. Ephedra. National Center for Complementary and Integrative Health. Available at https://www.nccih.nih.gov/health/ephedra. July 2020; Accessed: January 21, 2023.

11. Kenagy DN, Bird CT, Webber CM, Fischer JR. Dextroamphetamine use during B-2 combat missions. Aviat Space Environ Med. 2004 May. 75(5):381-6. [QxMD MEDLINE Link].

12. Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013 May 1. 129(3):167-79. [QxMD MEDLINE Link].

13. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One. 2010 Dec 7. 5(12):e15269. [QxMD MEDLINE Link]. [Full Text].

14. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009 Jul. 104(7):1085-99. [QxMD MEDLINE Link].

15. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009 May. 60(2):379-407. [QxMD MEDLINE Link]. [Full Text].

16. Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2017 May 1. 74 (5):511-519. [QxMD MEDLINE Link]. [Full Text].

17. Shin EJ, Dang DK, Tran TV, Tran HQ, Jeong JH, Nah SY, et al. Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res. 2017 Apr. 40 (4):403-428. [QxMD MEDLINE Link].

18. Katsumata S, Sato K, Kashiwade H, et al. Sudden death due presumably to internal use of methamphetamine. Forensic Sci Int. 1993 Dec. 62(3):209-15. [QxMD MEDLINE Link].

19. Kashani J, Ruha AM. Methamphetamine toxicity secondary to intravaginal body stuffing. J Toxicol Clin Toxicol. 2004. 42(7):987-9. [QxMD MEDLINE Link].

20. Kirkpatrick MG, Gunderson EW, Levin FR, Foltin RW, Hart CL. Acute and residual interactive effects of repeated administrations of oral methamphetamine and alcohol in humans. Psychopharmacology (Berl). 2011 Jul 12. [QxMD MEDLINE Link].

21. Zhang JX, Zhang da M, Han XG. Identification of impurities and statistical classification of methamphetamine hydrochloride drugs seized in China. Forensic Sci Int. 2008 Nov 20. 182(1-3):13-9. [QxMD MEDLINE Link]. [Full Text].

22. DrugFacts: Methamphetamine. National Institute on Drug Abuse. Available at http://www.drugabuse.gov/publications/drugfacts/methamphetamine. May 2019; Accessed: January 21, 2023.

23. Santos AP, Wilson AK, Hornung CA, Polk HC Jr, Rodriguez JL, Franklin GA. Methamphetamine laboratory explosions: a new and emerging burn injury. J Burn Care Rehabil. 2005 May-Jun. 26(3):228-32. [QxMD MEDLINE Link].

24. Burton BT. Heavy metal and organic contaminants associated with illicit methamphetamine production. NIDA Res Monogr. 1991. 115:47-59. [QxMD MEDLINE Link].

25. Conn C, Dawson M, Baker AT, et al. Identification of n-acetylmethamphetamine in a sample of illicitly synthesized methamphetamine. J Forensic Sci. 1996 Jul. 41(4):645-7. [QxMD MEDLINE Link].

26. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, et al. 2021 Annual Report of the National Poison Data System(©) (NPDS) from America's Poison Centers: 39th Annual Report. Clin Toxicol (Phila). 2022 Dec. 60 (12):1381-1643. [QxMD MEDLINE Link]. [Full Text].

27. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: Trends and Developments. Luxembourg: Publications Office of the European Union; 2020. [Full Text].

28. Lai FY, O'Brien JW, Thai PK, Hall W, Chan G, Bruno R, et al. Cocaine, MDMA and methamphetamine residues in wastewater: Consumption trends (2009-2015) in South East Queensland, Australia. Sci Total Environ. 2016 Jun 17. [QxMD MEDLINE Link].

29. Lappin JM, Darke S, Farrell M. Stroke and methamphetamine use in young adults: a review. J Neurol Neurosurg Psychiatry. 2017 Dec. 88 (12):1079-1091. [QxMD MEDLINE Link].

30. Swanson SM, Sise CB, Sise MJ, Sack DI, Holbrook TL, Paci GM. The scourge of methamphetamine: impact on a level I trauma center. J Trauma. 2007 Sep. 63(3):531-7. [QxMD MEDLINE Link].

31. Chiu ZK, Bennett IE, Chan P, Rosenfeld JV. Methamphetamine-related brainstem haemorrhage. J Clin Neurosci. 2016 Jun 23. [QxMD MEDLINE Link].

32. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012 Aug. 86(8):1167-231. [QxMD MEDLINE Link].

33. Neeki MM, Kulczycki M, Toy J, Dong F, Lee C, Borger R, et al. Frequency of Methamphetamine Use as a Major Contributor Toward the Severity of Cardiomyopathy in Adults ≤50 Years. Am J Cardiol. 2016 May 29. [QxMD MEDLINE Link].

34. Rommel N, Rohleder NH, Koerdt S, Wagenpfeil S, Härtel-Petri R, Wolff KD, et al. Sympathomimetic effects of chronic methamphetamine abuse on oral health: a cross-sectional study. BMC Oral Health. 2016 May 26. 16 (1):59. [QxMD MEDLINE Link]. [Full Text].

35. Pflügner A, Thome U, Bernhard MK, Vogel M, Bläser A, Nickel P, et al. [Methamphetamine Consumption During Pregnancy and its Effects on Neonates]. Klin Padiatr. 2017 Nov 28. [QxMD MEDLINE Link].

36. Brinker MJ, Cohen JG, Sharrette JA, Hall TA. Neurocognitive and neurodevelopmental impact of prenatal methamphetamine exposure: A comparison study of prenatally exposed children with nonexposed ADHD peers. Appl Neuropsychol Child. 2017 Nov 29. 1-8. [QxMD MEDLINE Link].

37. Diercks DB, Kirk JD, Turnipseed SD, Amsterdam EA. Evaluation of patients with methamphetamine- and cocaine-related chest pain in a chest pain observation unit. Crit Pathw Cardiol. 2007 Dec. 6(4):161-4. [QxMD MEDLINE Link].

38. Hawley LA, Auten JD, Matteucci MJ, Decker L, Hurst N, Beer W, et al. Cardiac complications of adult methamphetamine exposures. J Emerg Med. 2013 Dec. 45(6):821-7. [QxMD MEDLINE Link].

39. Won S, Hong RA, Shohet RV, Seto TB, Parikh NI. Methamphetamine-Associated Cardiomyopathy. Clin Cardiol. 2013 Aug 27. [QxMD MEDLINE Link].

40. Turnipseed SD, Richards JR, Kirk JD. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003 May. 24(4):369-73. [QxMD MEDLINE Link].

41. Watts DJ, McCollester L. Methamphetamine-induced myocardial infarction with elevated troponin I. Am J Emerg Med. 2006 Jan. 24(1):132-4. [QxMD MEDLINE Link].

42. Davis GG, Swalwell CI. Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse. J Forensic Sci. 1994 Nov. 39(6):1481-5. [QxMD MEDLINE Link].

43. Gold MS, Kobeissy FH, Wang KK, Merlo LJ, Bruijnzeel AW, Krasnova IN, et al. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry. July 2009. 66:118-27. [QxMD MEDLINE Link]. [Full Text].

44. Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med. 1988 Mar. 6(2):131-3. [QxMD MEDLINE Link].

45. Bowyer JF, Thomas M, Schmued LC, Ali SF. Brain region-specific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier. Ann N Y Acad Sci. 2008 Oct. 1139:127-39. [QxMD MEDLINE Link].

46. Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson's disease. Parkinsons Dis. 2013. 2013:308052. [QxMD MEDLINE Link]. [Full Text].

47. Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest. 1995 Oct. 108(4):1140-9. [QxMD MEDLINE Link].

48. Nestor TA, Tamamoto WI, Kam TH, Schultz T. Crystal methamphetamine-induced acute pulmonary edema: a case report. Hawaii Med J. 1989 Nov. 48(11):457-8, 460. [QxMD MEDLINE Link].

49. Thompson CA. Pulmonary arterial hypertension seen in methamphetamine abusers. Am J Health Syst Pharm. 2008 Jun 15. 65(12):1109-10. [QxMD MEDLINE Link].

50. Cohen AL, Shuler C, McAllister S, Fosheim GE, Brown MG, Abercrombie D, et al. Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections. Emerg Infect Dis. 2007 Nov. 13(11):1707-13. [QxMD MEDLINE Link].

51. Johnson TD, Berenson MM. Methamphetamine-induced ischemic colitis. J Clin Gastroenterol. 1991 Dec. 13(6):687-9. [QxMD MEDLINE Link].

52. Richards JR, Brofeldt BT. Patterns of tooth wear associated with methamphetamine use. J Periodontol. 2000 Aug. 71(8):1371-4. [QxMD MEDLINE Link].

53. Hamamoto DT, Rhodus NL. Methamphetamine abuse and dentistry. Oral Dis. 2009 Jan. 15(1):27-37. [QxMD MEDLINE Link].

54. Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007 Apr. 102 Suppl 1:70-5. [QxMD MEDLINE Link].

55. Smit AA, Wieling W, Voogel AJ, Koster RW, van Zwieten PA. Orthostatic hypotension due to suppression of vasomotor outflow after amphetamine intoxication. Mayo Clin Proc. 1996 Nov. 71(11):1067-70. [QxMD MEDLINE Link].

56. Yeo KK, Wijetunga M, Ito H, Efird JT, Tay K, Seto TB, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb. 120(2):165-71. [QxMD MEDLINE Link].

57. Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med. 1997 Sep. 4(3):130-5. [QxMD MEDLINE Link].

58. Cherner M, Letendre S, Heaton RK. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005. 64:1343-47. [QxMD MEDLINE Link].

59. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med. 1999 Nov. 17(7):681-5. [QxMD MEDLINE Link].

60. Stewart JL, Meeker JE. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol. 1997 Oct. 21(6):515-7. [QxMD MEDLINE Link].

61. Catanzarite VA, Stein DA. Crystal' and pregnancy--methamphetamine-associated maternal deaths. West J Med. 1995 May. 162(5):454-7. [QxMD MEDLINE Link].

62. Ramamoorthy JD, Ramamoorthy S, Leibach FH, Ganapathy V. Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol. 1995 Dec. 173(6):1782-7. [QxMD MEDLINE Link].

63. Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009 Apr. 67 (4):455-9. [QxMD MEDLINE Link]. [Full Text].

64. Woman gets 30 years for baby’s death from meth-tainted milk. AP News. Available at https://apnews.com/article/indiana-plymouth-ee9695401ea63f8603b560898cae4e38. Accessed: January 21, 2023.

65. Bulakci M, Cengel F. The role of radiology in diagnosis and management of drug mules: an update with new challenges and new diagnostic tools. Br J Radiol. 2016. 89 (1060):20150888. [QxMD MEDLINE Link].

66. McKinney PE, Tomaszewski C, Phillips S, Brent J, Kulig K. Methamphetamine toxicity prevented by activated charcoal in a mouse model. Ann Emerg Med. 1994 Aug. 24(2):220-3. [QxMD MEDLINE Link].

67. Thanacoody R, Caravati EM, Troutman B, Höjer J, Benson B, Hoppu K, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila). 2015 Jan. 53 (1):5-12. [QxMD MEDLINE Link].

68. Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015 May 1. 150:1-13. [QxMD MEDLINE Link].

69. [Guideline] Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department. J Emerg Med. 2015 Jul. 49 (1):91-7. [QxMD MEDLINE Link]. [Full Text].

70. Derlet RW, Albertson TE, Rice P. Protection against d-amphetamine toxicity. Am J Emerg Med. 1990 Mar. 8(2):105-8. [QxMD MEDLINE Link].

71. Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127 cases. J Emerg Med. 1989 Mar-Apr. 7(2):157-61. [QxMD MEDLINE Link].

72. Cisewski D, Long B, Gottlieb M. Emergency medicine updates: Droperidol. Am J Emerg Med. 2022 Mar. 53:180-184. [QxMD MEDLINE Link].

73. Matteucci MJ, Auten JD, Crowley B, Combs D, Clark RF. Methamphetamine exposures in young children. Pediatr Emerg Care. 2007 Sep. 23(9):638-40. [QxMD MEDLINE Link].

74. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005 Nov. 88 Suppl 3:S43-52. [QxMD MEDLINE Link].

75. Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol. 2000 Jun. 20(3):393-4. [QxMD MEDLINE Link].

76. Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997 Aug. 154(8):1170. [QxMD MEDLINE Link].

77. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009 Jan 21. CD003026. [QxMD MEDLINE Link].

78. Lam RP, Yip WL, Wan CK, Tsui MS. Dexmedetomidine use in the ED for control of methamphetamine-induced agitation. Am J Emerg Med. 2017 Apr. 35 (4):665.e1-665.e4. [QxMD MEDLINE Link].

79. Tobias JD. Dexmedetomidine to control agitation and delirium from toxic ingestions in adolescents. J Pediatr Pharmacol Ther. 2010 Jan. 15(1):43-8. [QxMD MEDLINE Link]. [Full Text].

80. Ibrahim F, Viswanathan R. Management of agitation following aneurysmal subarachnoid hemorrhage: is there a role for Beta-blockers?. Case Rep Psychiatry. 2012. 2012:753934. [QxMD MEDLINE Link]. [Full Text].

81. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med. 1993 Jun. 94(6):608-10. [QxMD MEDLINE Link].

82. Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010 Aug. 27(8):586-9. [QxMD MEDLINE Link].

83. Hysek C, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, et al. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol. 2012 Aug. 166(8):2277-88. [QxMD MEDLINE Link]. [Full Text].

84. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 May 10. 57(19):e215-367. [QxMD MEDLINE Link].

85. McKetin R, Najman JM, Baker A, Lubman DI, Dawe S, Ali R, et al. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). Addiction. 2012 May 7. [QxMD MEDLINE Link].

86. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011 Mar. 37 (2):131-6. [QxMD MEDLINE Link].

87. Bagheri M, Mokri A, Khosravi A, Kabir K. Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community. Int J High Risk Behav Addict. 2015 Sep 1. 4 (3):e23903. [QxMD MEDLINE Link].

88. Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investig Drugs. 2017 May. 26 (5):563-578. [QxMD MEDLINE Link].

John R Richards, MD, FAAEM Professor, Department of Emergency Medicine, University of California, Davis, Medical Center

John R Richards, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Robert W Derlet, MD Professor of Emergency Medicine, University of California at Davis School of Medicine; Chief Emeritus, Emergency Department, University of California at Davis Health System

Robert W Derlet, MD is a member of the following medical societies: American Academy of Emergency Medicine, American Association for the Advancement of Science, Infectious Diseases Society of America, Society for Academic Emergency Medicine, Wilderness Medical Society

Disclosure: Nothing to disclose.

Timothy E Albertson, MD, PhD, MPH Distinguished Professor of Pharmacology and Toxicology, Distinguished Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Chair, Department of Internal Medicine, University of California, Davis, School of Medicine; Distinguished Professor of Anesthesiology, Professor of Emergency Medicine and Clinical Toxicology, Davis Medical Center; Medical Director of Poison Control System, University of California, San Francisco, School of Pharmacy

Timothy E Albertson, MD, PhD, MPH is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Fred Harchelroad, MD, FACMT, FAAEM, FACEP Attending Physician in Emergency Medicine and Medical Toxicology, Excela Health System

Fred Harchelroad, MD, FACMT, FAAEM, FACEP is a member of the following medical societies: American College of Medical Toxicology

Disclosure: Nothing to disclose.

Jeter (Jay) Pritchard Taylor, III, MD Assistant Professor, Department of Surgery, University of South Carolina School of Medicine; Attending Physician / Clinical Instructor, Compliance Officer, Department of Emergency Medicine, Prisma Health Richland Hospital

Jeter (Jay) Pritchard Taylor, III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Columbia Medical Society, Society for Academic Emergency Medicine, South Carolina College of Emergency Physicians, South Carolina Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Employed contractor - Chief Editor for Medscape.

Edward A Michelson, MD Associate Professor, Program Director, Department of Emergency Medicine, University Hospital Health Systems of Cleveland

Edward A Michelson, MD is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article